Company CVAbout Gujarat Terce Laboratories Ltd 
Gujarat Terce Laboratories Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Gujarat Terce Laboratories Limited, incorporated in 1985, produces branded generic formulations for the domestic market. Over its more than three-decade business journey, the Company developed an extensive product basket comprising 50 brands covering multiple therapeutic areas which are marketed by its 180+ strong MR team across 13 Indian states.
Company Coordinates
Company Details
122/2 Ravi Estate, Bileshwarpura Chhatral Gandhinagar Gujarat : 382729
Registrar Details
Bigshare Services Pvt Ltd , E-2 , Ansa Industrial Estate, Saki Vihar Road, Saki Naka, Andheri (E), Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 7.42 Cr
Number of Shares
74.2 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
19-Jan-2011
74.2
7.42
2500000
10
Conversion of Warrants
19-Jan-2011
74.2
7.42
2500000
10
Conversion of Warrants
30-Sep-2008
49.2
4.92
1025000
10
Allotment of Equity Shares To Promoter & Others
30-Sep-2008
49.2
4.92
1025000
10
Allotment of Equity Shares To Promoter & Others
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Non Institution
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
Abundant Trade Link Private Limited (14.5%)
Highest Public shareholder
Sagar Saxena (1.39%)
Individual Investors Holdings
58.49%
Board of Directors
Management
Designation
Remuneration
Amrutbhai P Prajapati
Whole-time Director
4.05 lacs
Chhayaben Ashwinbhai Shah
Independent Director
0
Viplav Suryakantbhai Khamar
Independent Director
0
Aalap Prajapati
Managing Director & CEO
13.77 lacs
Surendra Kumar Sharma
Independent Director
0
Navinchandra Patel
Independent Director
0
Natwarbhai P Prajapati
Chairman & Wholetime Director
18.1 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Other Sales - Pharmaceutical Division
25.85
83.29%
Acolate Kid Susp. - Traded
1.20
3.87%
Acolate P Plus Tablet - Traded
1.06
3.40%
Other Sales - Pharmaceutical Division
Other Sales - Pharmaceutical Division
Acolate Kid Susp. - Traded
Acolate Kid Susp. - Traded
Acolate P Plus Tablet - Traded
Acolate P Plus Tablet - Traded
Stock DNARevenue and Profits:
Net Sales:
13 Cr
(Quarterly Results - Sep 2025)
Net Profit:
1 Cr
Pharmaceuticals & Biotechnology
INR 36 Cr (Micro Cap)
NA (Loss Making)
34
0.00%
-0.32
-13.62%
4.72
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
